A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-Muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Sunitinib (Primary) ; BCG
- Indications Bladder cancer; Urethral cancer
- Focus Therapeutic Use
- 19 Apr 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 07 Aug 2015 Planned End Date changed from 1 Jun 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 07 Aug 2015 Planned primary completion date changed from 1 Jun 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.